Statistics from Altmetric.com
Müller and colleagues recently reported that N88K is a frequent mutation in RAPSN.5 By genotyping 17 mutant K88 chromosomes for two RAPSN polymorphisms (IVS3-11delC and 456T/C) and a microsatellite marker D11S4117 (fig 1A) in 12 patients from 10 independent central or western European families, they found that 14 of 17 mutant chromosomes shared a common haplotype and concluded that N88K arises from a common founder.
Richard and colleagues also recently reported that N88K arises from a common founder; they genotyped 10 mutant K88 chromosomes in five patients from four families and from five healthy controls heterozygous for N88K.6 They showed that 9/10 mutant chromosomes shared a common haplotype for D11S1252, D11S4109, and D11S4117 (fig 1A). Both groups also demonstrated that a distant microsatellite marker, D11S986, was not linked to N88K.5,6
We also searched for a founder effect for N88K in our cohort of patients using six microsatellite markers and five RAPSN polymorphisms, and found that there is no founder haplotype for N88K.
MATERIALS AND METHODS
Our cohort comprised 10 unrelated white North American families consisting of 12 affected and 32 unaffected members, who carried a total of 12 mutant K88 chromosomes and 37 wild type N88 chromosomes. Patient 1 is case 1 in one previous report,3 and patients 3, 4, 6, and 7 are cases 1–4 in another report.2 Patients 2 and 9 have been reported in an abstract.7
Patients 5, 8, and 10 (all boys, 10, 4, and 8 years of age, respectively) have had mild to moderate myasthenic symptoms since birth, negative tests for anti-acetylcholine receptor antibodies, and respond partially to anti-cholinesterase medications.
DNA was isolated from muscle and blood as described.8 To identify RAPSN mutations, we directly sequenced eight RAPSN exons and their flanking noncoding regions. We employed allele specific PCR to screen 200 normal alleles for R151P and A142D. We analysed six microsatellite markers at D11S4174, D11S1385, D11S1344, D11S1252, D11S4109, and D11S4117 (fig 1A) using the GeneScan Analysis software (Applied Biosystems, Foster City, CA, USA) as previously described,3 and traced five RAPSN polymorphisms (−365G/A, IVS1-15C/T, 456T/C, IVS3-11delC, and 1298C/T) by direct sequencing using fluorescently labelled dideoxy terminators. Position +1 for –365G/A represents the transcriptional start site,3 whereas position +1 for 456T/C and 1298C/T corresponds to the translational start site. We used an ABI377 DNA sequencer (Applied Biosystems) for both direct sequencing and microsatellite marker analysis.
Mutations in RAPSN, a gene encoding rapsyn, a molecule that clusters acetylcholine receptors at the motor endplate, cause endplate acetylcholine receptor deficiency. N88K is a frequent mutation in RAPSN.
Two recent reports from Europe demonstrate a founder effect for N88K.
By analysing six microsatellite markers and five intragenic single nucleotide polymorphisms of 12 mutant K88 chromosomes and 37 wild type N88 chromosomes in 12 affected and 32 unaffected members from 10 white North American families, we found that there is no founder haplotype for N88K.
Our studies indicate that N88K is an ancient founder mutation, but subsequent multiple recombination events and divergence of microsatellite markers have obscured a founder effect. Alternatively, N88K occurred independently and repeatedly in humans.
We also report three novel RAPSN mutations (C97X, R151P, and A142D).
For statistical analysis, we employed Fisher’s two tailed exact test.
Patients 4 and 6 are homozygous for N88K, whereas other patients are heterozygous for N88K. Some patients also have a heteroallelic second mutation: −27CG (patient 1),3 1177delAA (patient 2),7 L14P (patient 3),2 C97X (patient 5), 553ins5 (patient 7),2 R151P (Pt 8), E333X (Pt 9),7 and A142D (Pt 10) (fig 2). All missense mutations affect residues conserved across species (fig 2B). C97X, R151P, and A142D have not been reported to date. Neither R151P nor A142D was detected in 200 normal alleles.
Haplotype analysis of the 12 mutant chromosomes revealed 11 distinct haplotypes (fig 1B). One mutant haplotype was shared between families 8 and 10, although one respective marker was not informative in each family. No haplotype was shared among the 37 wild type chromosomes, or between the wild type and mutant chromosomes. No recombination event was observed in any family.
We next performed Fisher’s exact test using the wild type chromosomes in family members as controls to see if individual microsatellite markers and polymorphisms were linked to N88K. We found that D11S4174, D11S1385, D11S1252, D11S4109, and five RAPSN polymorphisms were not linked to N88K, whereas D11S1344 and D11S4117 were (fig 1A). The presence or absence of the linkage was independent of the distance to RAPSN. All the mutant chromosomes shared a common genotype at five RAPSN polymorphisms and D11S4117, whereas other microsatellite markers showed 2–5 divergent genotypes. Even when only RAPSN polymorphisms were taken into account, the shared haplotype was not linked to N88K (p = 0.09). The tightly linked marker D11S1344 demonstrated five divergent genotypes. D11S4109, which is only 142 kb from RAPSN towards the q terminal, showed four divergent genotypes.
Our data demonstrate that there is no founder haplotype for N88K. Shared genotypes at the five RAPSN polymorphisms and divergent genotypes at the flanking microsatellite markers indicate that N88K is an ancient mutation that occurred on a founder chromosome, but subsequent multiple recombination events and divergence of microsatellite markers have obscured a founder effect. Lack of statistical linkage of the five RAPSN polymorphisms to N88K, however, argues against this view. An alternative possibility is that N88K occurred independently and repeatedly in humans.
We analysed six microsatellite markers and five RAPSN polymorphisms, whereas Müller et al analysed one microsatellite and two RAPSN polymorphisms,5 and Richard et al analysed three microsatellite markers.6 Our analysis covered all the previously reported markers. Our data reveal a founder effect (p = 0.006), when only the D11S4117 marker and the two polymorphisms used by Müller et al5 are taken into account. Analysis including more markers, however, excludes a founder effect. Our data do not demonstrate a founder effect (p = 0.18) when the three microsatellite makers used by Richard et al6 are employed. This is partly because our cohort shows four divergent genotypes at D11S4109, whereas Richard et al observed a single genotype at D11S4109, which indicates that those patients probably originated from a restricted community.
Both Müller et al5 and Richard et al6 omitted genotypes at D11S986 on the basis that D11S986 is distant from RAPSN, and that D11S986 had no linkage to N88K. As D11S986 occurs 2.7 Mb towards the p terminal from RAPSN, which is not exceptionally distant compared with other markers (fig 1A), divergent genotypes at D11S986 may represent lack of a founder effect in their cohorts.
Lack of a founder haplotype for N88K in our cohort leads to two possibilities: N88K is an ancient founder mutation or N88K has multiple founders. The accumulating availability of single nucleotide polymorphisms will enable further dissection of a founder effect for N88K in the future.
This work was supported by the National Institutes of Health grant NS6277 and by a Muscular Dystrophy Association research grant to A G Engel.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.